Compare Becton Dickinson and Co (BDX) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs The Coca-Cola Co K — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while The Coca-Cola Co K trades at $86.32 (market cap $373.76B). The key difference: The Coca-Cola Co K is far larger — about 7.6× Becton Dickinson and Co's market cap, and The Coca-Cola Co K pays the higher dividend (2.44%). Which is the better fit depends on your goals.
| BDX | KO | |
|---|---|---|
Market Cap | $48.93B | $373.76B |
Sector | Health | Consumer Staples |
52-Week High | $185.39 | $89.08 |
52-Week Low | $138.62 | $65.67 |
Enterprise Value | $65.03B | $400.93B |
Dividend Yield | 2.34% | 2.44% |
Volume | — | 14,630,257 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
Coca-Cola (KO) trades at $86.87, down 0.21% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.97 exceeding the $0.92 forecast. Key valuation ratios include a P/E of 26.09 and ROE of 44.23%, while cash flow trends show robust operational performance. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.
The outlook remains positive with a consensus price target of $95.83, implying 10.3% upside. Strengths include a 64-year dividend growth streak and high profitability, but risks involve regional demand divergence and elevated debt levels. Analyst sentiment is bullish with 60% buy ratings, supporting a favorable investment case for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
